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This report from the Tuberculosis Chemotherapy Centre, Madras, summarizes the
progress over a 5-year period of 193 patients with newly diagnosed, sputum-positive
pulmonary tuberculosis who were admitted to a concurrent comparison of home and
sanatorium treatment for one year with isoniazid plus PAS. Previous reports have shown
that, despite the traditional advantages of sanatorium treatment-rest, adequate diet,
nursing and supervised drug-administration-the home patients responded nearly as well
as the sanatorium patients in the first year; further, the relapse rates over a 2-year period
of follow-up were similar. The findings in the present report are based on a 4-year period
of follow-up and extend these conclusions, the relapse rates over the period being 7 % for
the home patients and 10 % for the sanatorium patients.
Patients who failed to respond to treatment in the first year and those who had a
bacteriological relapse in the second or subsequent years were usually re-treated with
reserve regimens, first with streptomycin plus pyrazinamide and, if this was ineffective, with
cycloserine plus ethionamide. Considering the findings over the entire 5-year period, five
home patients and three sanatorium patients died from non-tuberculous causes. Of the
remainder, 5 % of the home patients and 6 % of the sanatorium patients died of tuberculosis,
4 % in each series had bacteriologically active disease at five years and 90 % and 89 %,
respectively, had bacteriologically quiescent disease at that time. These findings are very
encouraging, particularly for developing countries such as India, where tuberculosis is a
major problem and sanatorium beds are very few.
An earlier publication from the Tuberculosis
Chemotherapy Centre, Madras (1959), reported on
the findings of a controlled comparison of home
and sanatorium treatment of pulmonary tubercu-
losis, in which all patients received isoniazid plus
p-aminosalicylic acid (PAS) for one year. The
* From the Tuberculosis Chemotherapy Centre, Madras-
31, India. The Centre is under the joint auspices of the
Indian Council of Medical Research, the Madras State
Government, the World Health Organization and the
Medical Research Council of Great Britain.
results in the two series were similar in the first year.
Subsequently, all patients were followed up at home
and the present report deals with the progress in
the second, third, fourth and fifth years of all the
patients originally admitted to the comparison and
also gives the status of their disease at five years.
The relapse rates in the second and third years have
already been reported to be similar for the home
and sanatorium patients with bacteriologically
quiescent disease at one year (Velu et al., 1960a;
Devadatta et al., 1961).
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I. PLAN AND CONDUCT OF THE STUDY
CHEMOTHERAPY DURING THE 5-YEAR PERIOD
In the first year, the patients were prescribed
isoniazid plus PAS (approximately 4-6 mg/kg body-
weight of isoniazid and 0.2-0.3 g/kg of sodium
PAS) 1 to be taken in the form of cachets twice a day
(Tuberculosis Chemotherapy Centre, Madras, 1959).
The treatment policy for the second and third years
has been fully described elsewhere (Devadatta et al.,
1961). In brief, patients with bacteriologically
quiescent disease at one year (see definition overleaf)
were allocated at random to treatment for the second
year with isoniazid (approximately 4-6 mg/kg body-
weight daily, in a single tablet) or to a placebo,
calcium gluconate (500 mg daily, in a single tablet).
During the third year, half (selected at random) of
those who were treated with isoniazid in the second
year, and whose disease remained quiescent, con-
tinued to receive that drug and all the remaining
patients with quiescent disease received the placebo.
All patients with quiescent disease at three years
received the placebo daily in the fourth year. Those
with quiescent disease at four years did not receive
any medicament subsequently.
Patients with bacteriologically active disease at
one year (see definition overleaf) or those who had a
bacteriological relapse were usually treated with
streptomycin plus pyrazinamide in the first instance.
Patients who failed to respond to this regimen
received cycloserine with either ethionamide or
thioacetazone.2
In a small proportion (5%) of the patients, the
disease was classified at one year as of bacterio-
logically doubtful status (see definition overleaf).
The treatment received by these patients in the
second and subsequent years is described on page 542.
INVESTIGATIONS IN THE SECOND, THIRD, FOURTH
AND FIFTH YEARS
Patients with bacteriologically quiescent disease at
one year were examined clinically and radio-
graphically at monthly intervals in the second year,
and at 3-monthly intervals in the third, fourth and
1 For instance, a patient weighing 100 lb (45 kg) received
200 mg of isoniazid and 10 g of sodium PAS.
2 Thioacetazone is the recommended international non-
proprietary name (see World Health Organization, 1962)
for 4’-formylacetanilide thiosemicarbazone (thiacetazone,
Tb I-698).
fifth years. The planned intensity of bacteriological
examinations is set out in Table 1. The standard
procedure was to obtain 14 bacteriological speci-
mens in the second year, 9 in the third, 9 in the
fourth and 11 in the fifth year. Occasionally, extra
specimens were examined, especially if a positive
result had been obtained after a sequence of negative
results. Tests of sensitivity to isoniazid and PAS
were set up at each of these examinations if a
positive culture was obtained. The techniques.
employed for smear and culture examinations and
TABLE 1
PLANNED INTENSITY OF BACTERIOLOGICAL
EXAMINATIONS FOR PATIENTS
WITH BACTERIOLOGICALLY QUIESCENT DISEASE
AT ONE YEAR
Year
Second
Third
Fourth
Fifth
Month
13 to 23
24
27, 30 &
33
36
39, 42 &
45
45
51, 54 &
57
59 ½
60
Type and number of
specimens
One collection specimen a
or a pair of laryngeal swabs a
Two collection speci-
mens and a pair of laryn-
geal swabs
One collection specimen
and a pair of laryngeal swabs
Two collection specimens
and a pair of laryngeal
swabs
One collection specimen
and a pair of laryngeal swabs
Two collection specimens
and a pair of laryngeal swabs
One collection specimen
and a pair of laryngeal swabs
One collection specimen
and one supervised spot
specimen
Two collection specimens
and a pair of laryngeal swabs
Total specimens during the 4-year period of
follow-up
Total
number of
specimens
43
a For the method of obtaining the specimen, see Velu,
Narayana & Subbaiah (1961).
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following culture negativity at three or more con-
secutive monthly examinations.
sensitivity tests have been described in detail earlier,
as also the details of the grading of smear and
culture results and the definition of isoniazid
resistance (Tuberculosis Chemotherapy Centre,
Madras, 1959).
Patients with active or relapsed disease were
examined monthly throughout the period they were
receiving chemotherapy. The monthly examinations
included a chest radiograph, examination by smear
and culture of two collection specimens of sputum,
and examination by culture of a pair of laryngeal
swabs. Tests of sensitivity to the drugs the patient
was receiving were set up on one positive culture at
each of these examinations, using techniques
described previously (Tuberculosis Chemotherapy
Centre, Madras, 1959; Angel et al., 1963).
Bacteriologically active disease : that is, either
(a) serious radiographic deterioration with one or
more positive cultures necessitating a change of
chemotherapy during the first year; or
(b) cultures never all negative at three con-
secutive monthly examinations; or
(c) a total of two or more positive cultures at 10, 11
and 12 months following culture negativity at
three or more consecutive monthly examinations.
During the second, third, fourth and fifth years
COLLAPSE THERAPY AND RESECTION
The policy was not to use collapse therapy or
resection. In the event, two patients had surgical
treatment-one a pneumonectomy (see page 545)
and the other a decortication for a pyopneumothorax
with a bronchopleural fistula (see page 543).
Bacteriological relapse : that is, two or more
positive cultures in any 6-month period. In the
second year, this meant a total of two or more
positive cultures in seven consecutive monthly
examinations. In the subsequent years, when
examinations were performed every three months,
this meant a total of two or more positive cultures
in three consecutive 3-monthly examinations-for
example, at 30, 33 and 36 months.
DEFINITIONS USED IN THIS REPORT
At one year
At five years
Bacteriologically quiescent disease : that is, all
cultures (usually 7-9) negative at 10, 11 and 12
months.
Bacteriologically quiescent disease : 1 that is, all
cultures (usually 9) negative from 54 to 60 months,
inclusive.
Disease of bacteriologically doubtful status : that
is, a single positive culture at 10, 11 or 12 months,
Bacteriologically active disease : that is, a total of
two or more positive cultures from 54 to 60 months,
inclusive.
II. CLASSIFICATION OF PATIENTS
Of 193 patients who were admitted to the study
(Table 2), 96 were allocated to treatment at home
(home series) and 97 to treatment in sanatorium
(sanatorium series). The main analysis of the findings
in the first year (Tuberculosis Chemotherapy Centre,
Madras, 1959) concerned 163 patients (82 home,
81 sanatorium) who (a) had organisms sensitive to
isoniazid and PAS on admission, (b) had had no
previous chemotherapy (two had received up to
two weeks’ chemotherapy) and (c) had followed
the allocated treatment regimen for 12 months,
apart from minor variations, unless they died or
had a change of chemotherapy because of deterio-
ration; of these, 130 had bacteriologically quiescent
disease at one year, 10 had disease of bacterio-
logically doubtful status, 19 had active disease
and four had died (three of tuberculosis and the
fourth from electrocution). The remaining 30
patients (14 home, 16 sanatorium) were excluded
from the main analysis for reasons given in Table 2.
PLAN OF THE PRESENT REPORT
The progress in the second, third, fourth and fifth
years is described for patients with bacteriologically
1 Seven patients, who each produced one positive culture
between 54 and 60 months, are also included in this category.
In all seven, the culture was an isolated positive (see
definition on page 540).
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TABLE 2
CLASSIFICATION OF PATIENTS IN THE PRESENT REPORT
Patients included in the
main analysis a in the first
year, according to the
classification of their dis-
ease status at one year b
Patients excluded from
the main analysis in the
first year
(a) Bacteriologically quiescent disease
(b) Disease of bacteriologically doubtful status
(c) Bacteriologically active disease
(d) Death
Total . . . . . .
(a) Isoniazid-resistant organisms on admission
(b) PAS-resistant organisms on admission
(c) Previous chemotherapy of more than two
weeks’ duration, but with organisms sensitive
to isoniazid and PAS
(d) Prolonged desensitization to PAS
(e) Premature discharge from treatment
(f) Sanatorium stay of more than six weeks (home
patients)
(g) Non-tuberculous death from diseases which
influenced the course of the tuberculosis
Total . . . . . .
All patients admitted to the study . . . . . . . . . . . . . .
Home
60
7
13
2
82
14
96
Sana-
torium
70
3
6
2
81
16
97
Both
series
130
10
19
4
163
9
6
Section
of report in
which progress
is considered
Ill
IV
V
–
VII
a For definition, see preceding page.
b For details of classification, see preceding page.
quiescent disease at one year in section III, for those included in the main analysis in section VI. Section
with disease of bacteriologically doubtful status at VII summarizes the disease status at five years of all
one year in section IV, for patients with active the 193 patients admitted to the study. (See also
disease at one year in section V and for patients not Table 2.)
III. THE PROGRESS OF PATIENTS WITH BACTERIOLOGICALLY QUIESCENT DISEASE
AT ONE YEAR DURING A 4-YEAR PERIOD OF FOLLOW-UP
Of the 130 patients with bacteriologically quiescent
disease, four were not allocated at random to
treatment in the second year for reasons given by
Velu et al. (1960a). Their progress is reported on
page 542.
Of the remaining 126, 57 had been treated at home
in the first year (home series) and 69 in sanatorium
(sanatorium series); 65 were allocated to isoniazid
alone (isoniazid series) and 61 to calcium gluconate
(calcium series). On the basis of a postero-anterior
radiograph and tomograms, 42 of these were
classified by an independent assessor (Dr J. H.
Angel) as having residual cavitation at one year
(cavitated series) and 84 as having no residual
cavitation (non-cavitated series). Their progress is
now considered.
DEATHS
Three patients died during the 4-year period of
follow-up, all from non-tuberculous causes. One
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(home, cavitated, isoniazid) died suddenly in the end of the first year, that is, at the starting-point of
17th month, possibly due to a spontaneous pneumo- the study of relapse. The detailed findings have
thorax, another (home, non-cavitated, calcium) died been reported earlier by Velu et al. (1960a), who
in the 41st month from carcinoma of the bronchus, concluded that patients in the home series had rather
and the third (sanatorium, cavitated, calcium) died more extensive residual radiographic lesions than
in the 51st month from cirrhosis of the liver. These those in the sanatorium series as did the cavitated
patients had only negative cultures for 14, 39 and 49 compared with the non-cavitated series, while the
months, respectively, before death (apart from the calcium and the isoniazid series were fairly similar,
first, who had one positive culture two months both clinically and radiographically, at the end of
before death). the first year.
BACTERIOLOGICAL. RELAPSE IN THE 4-YEAR PERIOD OF
FOLLOW-UP
During the 4-year period of follow-up, 11 (8.7%)
patients had a bacteriological relapse, eight (6.3 %)
in the second year (that is, in the first year of follow-
up), one (0.8 %) in the third, none in the fourth and
two (1.6 %) in the fifth year. Thus, most of the
relapses occurred in the second year.
Table 3 presents the relapse rates for the 126
patients referred to above, according to:
(a) the place of treatment in the first year (home
or sanatorium);
(b) the cavitation status at the end of the first year
(cavitated or non-cavitated);
(c) the treatment received in the second year
(calcium or isoniazid).
The proportion of patients who had a bacterio-
logical relapse during the 4-year period of follow-up
was 7 % of 57 home patients, as compared with 10 %
of 69 sanatorium patients; 10% of 42 patients with
cavitation at one year, as compared with 8% of 84
with non-cavitated disease at one year; and 13 % of
61 who received calcium gluconate, as compared
with 5 % of 65 who received isoniazid alone. (The
intensity with which patients were examined bac-
teriologically during the 4-year period of follow-up
was similar for the two series in each of the three
contrasts above.) None of the differences is statis-
tically significant.
The two series in each of the above three contrasts
were compared for the condition of disease at the
In Table 4, the 126 patients with quiescent disease
at one year are classified into 8 subgroups according
to the place of treatment in the first year, the cavi-
tation status at the end of the first year and the
treatment during the second year; further, the
numbers of relapses are set out year by year. It will
be observed that, in patients with no residual
cavitation at one year, seven of 42 who received
TABLE 3
RELAPSE RATES DURING THE 4-YEAR PERIOD OF FOLLOW-UP
FOR THE THREE CONTRASTS
Contrast Totalpatients
Patients who had a
bacteriological relapse
during the 4-year period
of follow-up
Place of treatment in the first year
Cavitation status at one year
Treatment during the second year
538
Place of
treatment
during the
first year
Home
Sanatorium
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TABLE 4
PATIENTS IN THE EIGHT SUBGROUPS WHO HAD A BACTERIOLOGICAL RELAPSE
DURING THE 4-YEAR PERIOD OF FOLLOW-UP
Cavitation Treatment
status during the
at one year second year
Cavitated
Calcium
lsoniazid
Non-cavitated
Cavitated
Non-cavitated
Calcium
lsoniazid
Calcium
lsoniazid
Calcium
lsoniazid
All patients . . . . . . . . . .
Total
Patients who had a bacteriological relapse
patients
No. %
Second
11 1 (9) a 1
10 0 (0) 0
18 3 (17) 1
18 0 (0) 0
8 0 (0) 0
13 3 (23) 3
24 4 (17) 3
24 0 (0) 0
126 11 8.7 8
Year of relapse
Third Fourth
0 0
0 0
1 0
0 0
0 0
0 0
0 0
0 0
1 0
Fifth
0
0
a The parentheses indicate percentages based on fewer than 25 observations.
calcium gluconate in the second year had a relapse,
as compared with none of 42 who received isoniazid,
statistically a highly significant difference (P<0.02).
The findings were, however, different in patients with
residual cavitation at one year. Thus, one of 19
patients who received calcium gluconate had a
relapse, as compared with three of 23 who received
isoniazid. In conclusion, whereas isoniazid given
alone in the second year prevented relapse among
the patients with non-cavitated disease at one year,
it apparently conferred no benefit on the patients
with cavitated disease at one year.
ISONIAZID ALONE IN THE THIRD YEAR IN
THE PREVENTION OF BACTERIOLOGICAL RELAPSE
Sixty patients, who had received isoniazid alone
in the second year and had bacteriologically quies-
cent disease at two years, were allocated at random
to treatment in the third year, 30 to isoniazid alone
and 30 to calcium gluconate.
An analysis of the clinical and radiographic con-
dition of the two groups at the time of original
admission to treatment, at the end of one year and
at the end of two years showed no important differ-
ences between them (Devadatta et al., 1961). Also,
the intensity of bacteriological investigation during
the third, fourth and fifth years was similar. During
this period, there were no relapses in either the
isoniazid or the calcium group, which suggests that
the administration of isoniazid alone in the third
year did not apparently confer any benefit.
DETAILS OF THE PATIENTS WHO HAD
A BACTERIOLOGICAL RELAPSE
Table 5 gives the details of the 11 patients who had
a bacteriological relapse. Clear-cut radiographic
deterioration, confirmed by an independent assessor
(Dr K. S. Sanjivi), followed the bacteriological
relapse in 10 of these patients (including P154 in
whom it occurred at 62 months). The 11 th patient
(P181) produced positive cultures repeatedly.
At the time of relapse, six of the eight patients who
received calcium excreted isoniazid-sensitive orga-
nisms, as compared with one of the three who were
receiving isoniazid, and even in the case of this
patient, who was very irregular in taking isoniazid,
the next positive culture was isoniazid-resistant.
(All 11 patients had only isoniazid-sensitive cultures
during the first year of treatment.)
Nine of the 11 patients were treated with strepto-
mycin plus pyrazinamide. Four patients responded
favourably and had quiescent disease at five years.
Three patients (including one who refused strepto-
mycin injections) failed to respond to this regimen
TABLE 5
DETAILS OF THE PATIENTS WHO HAD A BACTERIOLOGICAL RELAPSE, THEIR SUBSEQUENT CHEMOTHERAPY AND DISEASE STATUS
AT FIVE YEARS
Serial
number
P163
P181
P159
P90
P132
P191
P182
P60
P34
P19
P154
Place of
treatment
during the
first year
Home
Sanatorium
Sanatorium
Sanatorium
Sanatorium
Sanatorium
Home
Sanatorium
Home
Sanatorium
Home
Cavitation
status at
one year
Cavitated Calcium
Cavitated
Cavitated
Cavitated
Non-cavitated Calcium 14, 15, 16, 25, 28 (6)
Non-cavitated Calcium 14, 15 (3), 16 (2)
Non-cavitated Calcium 16, 21, 24, 28, 30, 53, 54 (5)
Non-cavitated Calcium 17, 18, 19, 20, 21, 22
Non-cavitated Calcium 27 (2), 42, 45, 51, 54 (4)
Non-cavitated Calcium 43, 54 (3), 55 (4), 56 (2)
Non-cavitated Calcium 57, 60
Treatment
during the 
lsoniazid
lsoniazid
lsoniazid
Months at which one or more positlve
cultures were Isolated a
22, 23, 24 (2)
13, 15, 17, 18, 20, 21, 23, 24 (2), 25
15 (3)
18 (3), 22 (2), 23 (3)
Results of Month
lsoniazid- retreat-
sensitivity ment
tests b started
Chemotherapy c
S, S, U 24 SZ (18) 
e
- - -
All R
R
S, R, S
26 SZ (6)
17 SZ (25)
24 SZ (2); PH (4); CEP (3)
C, R, R, S, R
All S
S, S, U, S, S, S, S
S, S, U, S, S, U
All R
All S
29
17
54
22
54
56
Both S
SZ (18) Quiescent
SZ (8); PH (24) Quiescent
SZ (6) Active
SZ (9); PH (17) Quiescent
SZ (6) Active
PH (4) Active
Nil Active
a When more than one positive culture was obtained In a month, the number Is indicated In parentheses.
b S = sensitive: R = resistant; C = contaminated; U = untested.
c  H = lsoniazid; P = PAS: S = streptomycin; Z = pyrazinamide; C = cycloserine; E = ethionamide.
d For details of classification, see page 535.
e The figures In parentheses give the duration in months.
Disease status
at five years d
Quiescent
Quiescent
Quiescent
Tuberculous death
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and, because they had had a relapse with organisms
sensitive to isoniazid, were re-treated with isoniazid
plus PAS; two achieved quiescent disease at five
years and the third died of tuberculosis at 39 months
despite a further change of regimen to ethionamide,
cycloserine and PAS. At five years, the remaining
two patients had not completed 12 months of treat-
ment with streptomycin plus pyrazinamide; one had
had positive cultures throughout the six months of
treatment and the other, although having active
disease by definition, had had only negative cultures
at the last three monthly examinations. The 10th
patient, who had a relapse at 54 months with
isoniazid-sensitive organisms, had, at five years,
been treated with isoniazid plus PAS for four
months and had had negative cultures at the last
three monthly examinations. The 11 th patient, who
had a positive culture at 57 months, did not have
treatment restarted before the end of five years
because the second positive culture was only ob-
tained at 60 months. In summary, of the 11 patients
who had a bacteriological relapse, six had bacterio-
logically quiescent disease at five years, four had
active disease and one died of tuberculosis.
PROGNOSTIC IMPORTANCE OF VARIOUS FACTORS IN
THE OCCURRENCE OF RELAPSE
The prognostic importance of various factors in
the occurrence of relapse in the 4-year period have
been investigated. The erythrocyte sedimentation
rate (ESR), extent of cavitation and grade of smear
positivity of the sputum on admission were not of
prognostic importance, nor were the month of
sputum conversion in the first year and the ESR at
one year. However, of 29 patients who had uni-
lateral disease on admission to treatment and
bacteriologically quiescent disease at one year, none
had a relapse during the 4-year period of follow-up,
as compared with 11 of 97 patients who had bilateral
disease on admission; this difference does not, how-
ever, attain statistical significance (P=0.1). Simi-
larly, none of 32 patients who had unilateral disease
at one year had a relapse subsequently, as compared
with 11 of 90 patients who had bilateral disease
(P= 0.06).
PATIENTS WITH ISOLATED POSITIVE CULTURES
In this report, an isolated positive culture is
defined as one positive culture in any 6-month period
during the second or subsequent years. A total of 18
(14%) patients had an isolated positive culture
(Table 6), five of them in the second, one in the third,
seven in the fourth and five in the fifth year. Eleven
of the isolated positive cultures were obtained from
sputum specimens and all were negative on direct
smear examination; the remaining seven specimens
were from laryngeal swabs. A single colony grew in
seven of the cultures and only four cultures grew
more than 100 colonies (2+ or 3+ growth). The
organisms were sensitive to isoniazid in 10 of the
15 cultures with test results available (including three
from patients who were receiving isoniazid when the
culture was produced).
An isolated positive culture was produced by seven
(11%) of 61 patients who received the placebo in
the second year, as compared with 11 (17%) of 65
patients who received isoniazid in the second year
(P = 0.5). Of 84 patients with non-cavitated disease,
12 (14 %) had an isolated positive culture, as com-
pared with six (14%) of 42 patients with cavitated
disease. Thus, the occurrence of the isolated positive
result (sometimes even in the fifth year) was ap-
parently not influenced either by the cavitation
status at one year, or by whether or not the patient
had received isoniazid subsequently.
The occurrence of an isolated positive culture
result did not carry a bad prognosis. Thus, only
one (6%) of 18 patients with an isolated positive
culture had a relapse and one died of a non-tubercu-
lous cause; the remaining 16 patients had bacterio-
logically quiescent disease at five years and have
been regarded as having had bacteriologically
quiescent disease throughout the period of follow-up.
OTHER ASSESSMENTS OF PROGRESS
This subsection presents the findings of the radio-
graphic assessments and ESR determinations for the
112 patients who had bacteriologically quiescent
disease throughout the period of follow-up; of the
remaining 14 patients, 11 had a bacteriological
relapse and three died of non-tuberculous causes;
eight of the relapses and one of the deaths occurred
in the second year. All the radiographic assessments
were undertaken by an independent assessor (Dr Raj
Narain).
Changes in radiographic appearances
In 58 (52 %) of the 112 patients, changes in radio-
graphic appearances had occurred between one and
five years. There was improvement in 33 (29%),
which was classified as moderate in 2 and slight
in 31, and deterioration in 25 (22 %), which was
classified as moderate in 3 and slight in 22.
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TABLE 6
PATIENTS WHO PRODUCED AN ISOLATED POSITIVE CULTURE DURING THE 4-YEAR PERIOD OF FOLLOW-UP
Serial
number
Place of
treatment in the
first year
P66
P185
P152
Home
Sanatorium
Home
P30c
P59
P77
Home
Home
Home
P11
P15
P19
P158
Home
Sanatorium
Sanatorium
Sanatorium
P26 Home
P6 Sanatorium
P139 Sanatorium
P81 Sanatorium
P130 Home
P114 Sanatorium
P121 Home
P146 Sanatorium
Cavitation
status at
one year
Cavitated
Cavitated
Cavitated
Cavitated
Cavitated
Cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Non-cavitated
Treatment
during the
second year
Calcium
Calcium
Calcium
lsoniazid
lsoniazid
lsoniazid
Calcium
Calcium
Calcium
Calcium
lsoniazid
lsoniazid
lsoniazid
lsoniazid
lsoniazid
lsoniazid
lsoniazid
lsoniazid
Treatment
during the
third year
Calcium
Calcium
Calcium
–
Calcium
Calcium
Calcium
Calcium
Calcium
Calcium
Calcium
Calcium
Calcium
Calcium
Calcium
lsoniazid
lsoniazid
lsoniazid
42
42
45
15
48
54
16
24
43
60
13
14
39
54
60
36
45
59
Bacteriological results
Smear a
–
0
–
0
0
0
0
0
0
0
0
–
0
0
Culture
1+
1 colony
1 colony
1 +
1 +
1 colony
3 +
1 +
2 +
1 colony
4 colonies
1 +
1 colony
2 +
1 colony
16 colonies
1 colony
2 +
Result of
isoniazid-
sensitivity
test b
R
R
S
No growth
S
S
S
S
No growth
Contaminated
R
S
S
R
a A dash (–) indicates that the specimen was a laryngeal swab and therefore had no smear result.
b S = sensitive; R = resistant.
c This patient died in the 17th month (see page 636).
Radiographic changes, interpreted as deteriora-
tion (usually slight), occurred at some time or other
during the period of follow-up (four assessments
 were undertaken) in as many as 35 (31%) of the
patients.
Cavitation changes were assessed by using standard
radiographs and tomograms. Of 36 patients with
cavitation at one year, cavitation had disappeared by
five years in 33 %, had decreased in 36 %, had re-
mained unchanged in 11 % and had increased in
19 %. Of 76 patients with no cavitation at one year,
cavitation was present at five years in five (7%).
Thus, increase in or appearance of cavitation
occurred in 12 (11%) of the 112 patients with per-
sisting bacteriologically quiescent disease.
Erythrocyte sedimentation rate
The proportion of patients who had an elevated
ESR (more than 10 mm) was 75 % at one year, 70 %
at two years, 72 % at three years, 65 % at four years
and 60% at five years. The corresponding propor-
tions were 51%, 35 %, 43 %, 43 % and 34%, res-
pectively, for an ESR of 21 mm or more, and 12 %,
7 %, 11%, 13 % and 11%, respectively, for an ESR
of 51 mm or more.
In summary, minor radiographic changes (inter-
preted as deterioration), minor changes in cavitation
and elevated ESRs occurred not infrequently in
patients with persisting bacteriologically quiescent
disease.
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PATIENTS NOT ALLOCATED AT RANDOM chemotherapy and had negative cultures throughout
Of the four patients not included in the random the 4-year period, and the fourth (home, cavitated),
allocation to treatment (see page 536), one (home, who continued on isoniazid plus PAS, had a bacterio-
cavitated) died of carcinoma of the oesophagus in logical relapse in the 15th month with isoniazid-
the 15th month, having had negative cultures for resistant organisms, was treated with streptomycin
the preceding 13 months; two others (1 home, 1 plus pyrazinamide for 18 months and had quiescent
sanatorium; both non-cavitated) received no further disease at five years.
IV. PATIENTS WITH DISEASE OF BACTERIOLOGICALLY
DOUBTFUL STATUS AT ONE YEAR
Ten patients were classified as having disease of
bacteriologically doubtful status at one year (see
definition on page 535), the single positive culture
occurring in the 10th month in three, in the 11 th in
two and in the 12th in five patients. In the second
year, seven patients received calcium gluconate,
two isoniazid, and one continued on isoniazid plus
PAS. Five patients had negative cultures throughout
the 4-year period of follow-up. Two produced an
isolated positive culture at 33 and 54 months,
respectively, which was sensitive to isoniazid. In
the remaining three patients, the positive culture
obtained at 12 months proved to be the beginning
of a bacteriological relapse. One of these patients,
who received isoniazid in the second and third years,
had four positive cultures in the second year followed
by a series of negative cultures and then three more
positive results in the third year; she had one more
positive result at 39 months, but 22 subsequent
cultures were negative and the disease was quiescent
at five years. The remaining two patients were treated
with streptomycin plus pyrazinamide for 15 and
18 months, and had quiescent disease at five years.
In summary, the three patients who had a bacterio-
logical relapse had positive cultures at 12 and 13
months-that is, the positive culture at 12 months
proved to be the commencement of a relapse.
Finally, all 10 patients who had disease of bacterio-
logically doubtful status at one year had bacterio-
logically quiescent disease at five years.
V. PATIENTS WITH BACTERIOLOGICALLY ACTIVE DISEASE AT ONE YEAR
There were 19 patients with bacteriologically
active disease at one year (see definition on page 535);
their chemotherapy during the 4-year period of
follow-up and their disease status at five years are
set out in Table 7. One of the 11 who continued
with isoniazid plus PAS in the second year attained
and maintained bacteriologically quiescent disease as
did two of the three who received isoniazid alone.
In all, 16 patients received streptomycin plus pyra-
zinamide. Of these, seven had bacteriologically
quiescent disease at five years, one died from a non-
tuberculous cause (bronchial carcinoma), two
died of tuberculosis, and six others failed to respond
to treatment. Of the six patients who failed to
respond to treatment, four were treated with cyclo-
serine plus ethionamide; at five years, three of
these had bacteriologically quiescent disease and
the fourth, who was still under treatment, had had
only negative cultures at the last two monthly
examinations. The remaining two patients were
treated with cycloserine plus thioacetazone followed
by other regimens (see Table 7); one died of tuber-
culosis and the other had active disease at five
years.
In summary, of the 19 patients with bacterio-
logically active disease at one year, 13 had bacterio-
logically quiescent disease and two had bacterio-
logically active disease at 5 years; four had died,
three from tuberculosis and one from a non-
tuberculous cause.
Serial
number
P67
P43
P111
P23
P69
P100
P42
P115
P88
P127
P149
P179
P75
P177
P13
P38
P31
P135
P116
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TABLE 7
CHEMOTHERAPY DURING THE 4-YEAR PERIOD OF FOLLOW-UP AND DISEASE STATUS
AT FIVE YEARS FOR PATIENTS WITH BACTERIOLOGICALLY ACTIVE DISEASE AT ONE YEAR
Place of
treatment during
the first year
Home
Home
Sanatorium
Home
Home
Home
Sanatorium
Home
Home
Home
Sanatorium
Home
Home
Sanatorium
Home
Home
Sanatorium
Home
Sanatorium
Regimens of chemotherapy during the
4-year period of follow-up a
PH (12) c
H (24)
H (24)
SZ (24)
SZ (23)
SZ (21)
SZ (12)
SZ (9)
PH (12); SZ (24)
PH (12); SZ (24)
PH (12); SZ (24)
H (5); SZ (24)
PH (7); SZ (2)
PH (8); SZ (6); CE (18)
PH (12); SZ (9); CE (18)
PH (13); SZ (7); CE (18)
PH (14); SZ (1); CE (4)
PH (4); SZ (7); CT (3); CE (5); CH (10); H (3); EH (5)
PH (5); SZ (8); CT (12); H (3); CE (8)
5 4 3
Disease status
at five years b
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Non-tuberculous death
Tuberculous death
Quiescent
Quiescent
Quiescent
Quiescent
Tuberculous death
Quiescent
Quiescent
Quiescent
Active
Active
Tuberculous death
a H = lsoniazid; P = PAS; S = streptomycin: Z = pyrazinamide; C = cycloserine; E = ethionamide; T = thioacetazone.
b For details of classification, see page 535.
c The figures in parentheses give the duration in months.
VI. PATIENTS NOT INCLUDED IN THE MAIN ANALYSIS
Of the 30 patients excluded from the main
analysis, three died during the first year, one from
tuberculosis in the first month and two from non-
tuberculous causes in the eighth and ninth months,
respectively (Tuberculosis Chemotherapy Centre,
Madras, 1959). For the remaining 27 patients, the
chemotherapy during the 4-year period of follow-up
and the disease status at one and at five years are
set out in Table 8.
Of the eight patients with isoniazid-resistant
organisms on admission, two responded unfavour-
ably to treatment: one died of tuberculosis in the
18th month while receiving streptomycin plus pyra-
zinamide and the other had bacteriologically active
disease at five years in spite of having received five
different regimens of chemotherapy; both had had
active disease at one year. The remaining six patients,
two of whom had had active disease and four quies-
cent disease at one year, had quiescent disease at five
years (including one (P107) who had had a decortica-
tion for a pyopneumothorax with a bronchopleural
fistula). Four of these (including one of the cases
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TABLE 8
CHEMOTHERAPY DURING THE 4-YEAR PERIOD OF FOLLOW-UP AND DISEASE STATUS
AT ONE AND FIVE YEARS FOR PATIENTS EXCLUDED FROM THE MAIN ANALYSIS
Reason for exclusion Serial
from main analysis number
Isoniazid-resistant
organisms on admission
Premature discharge from
treatment
PAS-resistant organisms
on admission
Previous chemotherapy of
more than two weeks’ dura-
tion, but with organisms
sensitive to isoniazid and
PAS
Prolonged desensitization
to PAS
Sanatorium stay of more
than six weeks (home
patients)
P40
P64
Place of
treatment in
the first year
Disease Regimens of chemotherapy
status at
one year a
during the 4-year period
of follow-up b
Home Active
Sanatorium Active
P33
P98
P119
P107
P133
P29
Home Active
Home Active
Sanatorium Quiescent
Home Quiescent
Home Quiescent
Sanatorium Quiescent
P108
P126
P76
P73
P63
P93
P138
Sanatorium
Sanatorium
Sanatorium
Sanatorium
Sanatorium
Sanatorium
Sanatorium
Active
Active
Favourablea
Active
P25 Sanatorium Active
P27 Home Quiescent
P193 Home Quiescent
P24 Sanatorium Quiescent
P55 Home Quiescent
P151 Home Quiescent
P123
P22
P187
P188
P17
P113
Home Active
Sanatorium Quiescent
Sanatorium Quiescent
Home Quiescent
Sanatorium Quiescent H (12) Quiescent
Home Quiescent H (27) Quiescent
SZ (5) c
PH (12); SZ (10); CT (11);
CE (7); H (8)
PH (5); SZ (24)
–
SZ (8); CE (24)
SPH (2); PH (9)
H (27)
H (12)
CT (8) ; CE (2) ; ZE (2)
PH (7)
PH (13); H (6)
Received chemotherapy
elsewhere but details not
complete
PH (18); SZ (12)
H (24)
H (13)
PH (6); SZ (13)
PH (24)
H (24)
Disease status
at five years a
Tuberculous death
Active
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Tuberculous death
Tuberculous death
Active
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
Quiescent
a For details of classification, see page 535.
b H = isoniazid; P = PAS; S = streptomycin: Z = pyrazinamide; C = cycloserine; E = ethionamide; T = thioacetazone.
c The figures in parentheses’ give the duration In months.
d This patient had four negative cultures at 12 months.
e These patients had four, one and three negative cultures, respectively, at 12 months.
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with active disease at one year) did so without
receiving reserve regimens; the fifth, who had had
active disease at one year, attained quiescent disease
on streptomycin and pyrazinamide; and the sixth,
who had a relapse, attained quiescent disease on
cycloserine plus ethionamide after failing to respond
to streptomycin plus pyrazinamide.
Of the seven patients who discharged themselves
from treatment during the first year, three res-
ponded unfavourably: two died of tuberculosis (in
the 18th and 50th months, respectively), the first
having had no further chemotherapy after the first
year and the second while receiving his third reserve
regimen; the third patient, who was very uncoopera-
tive and had only had seven months of treatment
with isoniazid plus PAS after the first year, had
active disease at five years. The remaining four
patients, three of whom had received further chemo-
therapy (two at other tuberculosis clinics) and one,
who had apparently received no further treatment,
had quiescent disease at five years.
The remaining 12 patients attained quiescent
disease at five years (including one (P22) who had
had a pneumonectomy), the only two with active
disease at one year having subsequently received
treatment with a reserve regimen-namely, strepto-
mycin plus pyrazinamide.
In summary, at five years, 22 patients had bac-
teriologically quiescent disease, two had active
disease and six had died, four from tuberculosis and
two from non-tuberculous causes. The six patients
who were classified at five years as having had an
unfavourable response had either had isoniazid-
resistant organisms on admission or had dis-
charged themselves from treatment in the first
year.
VII. DISEASE STATUS AT FIVE YEARS OF ALL PATIENTS
There were 96 patients who were treated at home
and 97 patients who were treated in sanatorium in
the first year. During the subsequent four years,
12 of the home patients and 6 of the sanatorium
patients had to be hospitalized for tuberculous
conditions, a non-significant difference. The period
of hospitalization was less than one month in two
(1 home, 1 sanatorium), 1-3 months in four (3 home,
1 sanatorium), 3-6 months in four (3 home, 1
sanatorium), 6-12 months in four (3 home, 1 sana-
torium) and one year or more in four (2 home,
2 sanatorium).
During the 5-year period, eight patients (5 home,
3 sanatorium) died from non-tuberculous causes:
seven had consistently had negative cultures for
2, 4, 13, 14, 18, 39 and 49 months, respectively,
before death and the eighth (sanatorium) had
positive cultures at the time of death, which was
due to carcinoma of the tongue. Of the remaining
91 patients in the home series, 82 (90 %) had bacterio-
logically quiescent disease at five years, as compared
with 84 (89%) of the 94 sanatorium patients; five
(5 %) and six (6 %), respectively, had died of tubercu-
losis and four (4%) in each series had bacteriologi-
cally active disease (Table 9). Thus, the condition of
the home and sanatorium series was very similar
at five years. Considering both series together, 90%
of the patients had bacteriologically quiescent
disease at five years, 4% had active disease and 6%
had died of tuberculosis.
VIII. DISCUSSION
The present report is concerned with the progress
during a 5-year period of 193 patients with pul-
monary tuberculosis who were admitted to a con-
current comparison of home and sanatorium treat-
ment for one year with isoniazid plus PAS. The
patients had newly diagnosed, untreated and usually
far-advanced disease on admission to treatment, and
came mostly from the poorest sections of the com-
munity in Madras city. Unless their condition
necessitated a period of treatment in hospital (which
was uncommon), during the 4-year follow-up period
all the patients lived in their normal home environ-
ment-that is, they were housed in poor and over-
crowded accommodation, had a low dietary intake
and engaged in strenuous physical activity, often
working for long hours (Ramakrishnan et al., 1961b,
1966 1).
1 See article on page 553 of this issue.
TABLE 9
DISEASE STATUS AT FIVE YEARS FOR ALL HOME PATIENTS AND ALL SANATORIUM PATIENTS ADMITTED TO STUDY
Bacteriological classification of disease status at five years a
Home series Sanatorium series
Total
57
7
13
1
6
4
2
0
0
1
91
Active Total Tuberculousdeath
Quiescent
No. %
67 97
3 (100)
3 (60)
–  –
Tuberculous
death ActiveNo. %
Patients included In the main analysis In the first year b
(a) Bacteriologically quiescent disease at one year a
(b) Disease of bacteriologically doubtful status at one year a
(c) Bacteriologically active disease at one year a
(d) Tuberculous death In the first year
Patients excluded from the main analysis In the first year
(a) Isoniazid-resistant organisms on admission
(b) PAS-resistant organisms on admission
(c) Previous chemotherapy of more than two weeks’ duration,
but with organisms sensitive to isoniazid and PAS
(d) Prolonged desensitization to PAS
(e) Premature discharge from treatment
(f) Sanatorium stay of more than six-weeks (home patients)
Total patients. . . . . . . . . . . . . . . . . . . . . . . . . .
Non-tuberculous death during the 5-year period . . . . . . . . . 5
All patients admitted to study . . . . . . . . . . . . . . . . . . 96
54 95
7 (100)c
10 (77)
–  –
69
3
6
2
4 (67)
4 (100)
2 d
0
0
0
2 (67)
2 (100)
2 (100)
1 (100)
4 (57)
–  –
0
0
2 (100)
–  –
–  –
1 (100)
5 94 84 89 682 90
3–  –
97–  – –  –
a For details, see page 535.
b For definition, see page 535.
c The parentheses indicate percentages based on fewer than 25 observations.
d Including one in the first year.
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RELAPSE RATES IN PATIENTS WITH BACTERIOLOGICALLY
QUIESCENT DISEASE AT ONE YEAR
About 90% of the patients with bacteriologically
quiescent disease at one year maintained this state
throughout the 4-year period of follow-up. There
were 11 (8.7%) bacteriological relapses; eight of
these occurred in the first year of follow-up, so that
the risk of relapse was maximal during this period.
The relapse rate was no higher in the home series
than in the sanatorium series; thus, four (7%) of
57 home patients had a relapse, as compared with
seven (10 %) of 69 sanatorium patients.
Isoniazid alone, given in the second year, pre-
vented relapse among the patients with bacteriologi-
cally quiescent disease and no residual cavitation at
one year; none of 42 such patients had a relapse, as
compared with seven (17 %) of 42 who received a
placebo (calcium gluconate), statistically a highly
significant difference (P<0.02). On the other hand,
isoniazid alone in the second year apparently had
no effect in preventing relapses among the patients
with residual cavitation at one year, since three
(13 %) of 23 cavitated patients who received it had a
relapse, as compared with one (5 %) of 19 who
received the placebo.
A subsidiary study, based on random allocation,
showed that, in patients with bacteriologically
quiescent disease at two years following a year of
isoniazid plus PAS and a year of isoniazid alone, the
administration of isoniazid in the third year con-
ferred no apparent benefit, there being no relapses
in either the treated or the control group. Although
based on small numbers, this finding underlines
the importance of control groups in interpreting the
results of long-term chemotherapy studies and, in
particular, the need for caution in assessing recom-
mendations made by some workers for very pro-
longed chemotherapy (Doonief, Hite & Bloch,
1955; Hyde, 1960; Pfuetze, Watson & Pyle, 1960;
Worobec, Kramer & Fox, 1960).
Thomas (1965) reported 1.7 % of relapses in a
5-year follow-up of 483 sputum-positive patients
(72 more could not be followed up), notified in
Birmingham, England, who had been treated daily
for about two years, first with the three main anti-
tuberculosis drugs and subsequently, when pre-
treatment sensitivity test results became available,
by an appropriate 2-drug regimen; all the patients
were in hospital for an “ adequate ” period of time
and completed a period of therapy “ to the satis-
faction of the physician ”. Horne (1964; personal
communication, 1965) from Edinburgh reported a
relapse rate of 2.8%, over an average follow-up
of about six years (range 3-9 years), in 761 sputum-
positive patients who had been successfully treated
with tripledrug chemotherapy followed by a 2-drug
regimen. (Over 10% of these patients had surgi-
cal treatment.) He found that the relapse rates
were influenced by the duration of treatment; thus
seven of 10 patients who had received less than six
months’ chemotherapy had a relapse, as compared
with 13 of 171 who had received treatment for
6-18 months and one of 580 who had more than
18 months of treatment. Although the relapse rate
of 8.7 % for the 4-year follow-up in the present study
is higher than those reported above, it cannot be
regarded as unduly high in view of the regimen used
and the duration of chemotherapy. Furthermore, if
the patients with no residual cavitation at one year
had all received isoniazid in the second year, and
those with residual cavitation had continued with
isoniazid plus PAS (see Great Britain, Medical
Research Council, 1962), then the relapse rate
would, in all probability, have been substantially
lower than that reported here. However, if for
economic or administrative reasons (Fox, 1964) it is
not feasible to administer chemotherapy for more
than one year, it is likely that a routine re-examina-
tion at two years would detect the majority of
relapses, if indeed the patients had not already
presented themselves for reexamination because of a
recurrence of symptoms.
There has been considerable uncertainty con-
cerning the prognosis of patients with the “ open-
negative ” syndrome, but there is increasing evidence
that this is not in itself a particularly dangerous state
(Ryder, 1958; Worobec, 1959; Hyde, 1961). Our
findings lend support to this view for, considering
only those patients who received the placebo in the
second year and thus had only one year of chemo-
therapy (isoniazid plus PAS), one (5%) of 19 with
residual cavitation at one year had a relapse, as
compared with seven (17%) of 42 without cavita-
tion.
OCCURRENCE OF ISOLATED POSITIVE CULTURES
A positive culture occurring as an isolated event
in any 6-month period, sometimes as late as the fifth
year, was found in 18 (14 %) of the patients with
quiescent disease at one year, thus showing that,
even in patients who did not have a bacteriological
relapse, chemotherapy failed in some to be sterilizing.
These isolated positive cultures usually showed only
a very few colonies, were often isoniazid-sensitive and
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were infrequently followed by a relapse (1 (6 %) of 18
patients). This supports the observations of Raleigh
(1957), Velu et al. (1960a, 1961a) and Devadatta et
al. (1961) that an isolated positive result in patients
with quiescent disease, who are under intensive
bacteriological investigation, does not carry a bad
prognosis.
OTHER ASSESSMENTS OF PROGRESS
This study has shown that measurements of ESR
and assessments of changes in radiographic appear-
ances and cavitation can often be misleading in
following the progress of patients with bacterio-
logically quiescent disease. Thus, in patients with
persisting quiescent disease over a 4-year period,
radiographic changes, interpreted as deterioration,
occurred at some time or other in 31 %, increase in or
appearance of cavitation occurred at five years in
about 10%, and an elevated ESR was obtained for
at least 60% of the patients at each of the yearly
examinations.
THE RE-TREATMENT OF PATIENTS WITH ACTIVE
OR RELAPSED DISEASE
Streptomycin plus pyrazinamide has been found
to be an effective 2-drug regimen in the re-treatment
of patients excreting isoniazid-resistant organisms,
who had either failed to attain bacteriologically
quiescent disease with the initial regimen of isoniazid
plus PAS or who had a bacteriological relapse sub-
sequently (Velu et al., 1960b, 1961b). Of the 34
patients in the present study who were treated with
streptomycin plus pyrazinamide, one became unco-
operative in the second month and refused further
injections, one died of a non-tuberculous cause
and two were still under treatment at five years.
Of the remaining 30 patients, 17 (57%) achieved
bacteriological quiescence of the disease.
Cycloserine plus ethionamide has also been found
to be an effective 2-drug reserve regimen (Angel et
al., 1963; Ramakrishnan et al., in preparation). In
the present study, of five patients who received
cycloserine plus ethionamide as a “ third-line”
regimen after failing to respond to streptomycin plus
pyrazinamide, four had a favourable response while
the fifth was still under treatment at five years. In
contrast, cycloserine plus thioacetazone was dis-
appointing, for all four patients who received it had
an unfavourable response (see also Angel et al.,
1963).
DISEASE STATUS AT FIVE YEARS OF ALL PATIENTS
ORIGINALLY ADMITTED TO THE STUDY
It is of interest to consider the disease status at
five years of all the patients admitted to treatment
in the first year at home (96 patients) or in sana-
torium (97 patients). Death due to a non-tuberculous
cause occurred in five home and three sanatorium
patients. Considering the remainder, 90% of the
home patients and 89% of the sanatorium patients
had bacteriologically quiescent disease at five years,
4% in each series had bacteriologically active
disease and 5 % and 6%, respectively, had died of
pulmonary tuberculosis. It is noteworthy that only
two patients, one in each series, had surgical treat-
ment.
Considering all 193 patients admitted to the study,
eight died of non-tuberculous causes and, of the
remaining 185, 90 % had bacteriologically quiescent
disease at five years, 4% had active disease and 6%
had died of tuberculosis. There was some evidence,
albeit based on small numbers, that the outcome
at five years was, relatively frequently, unfavourable
in patients who had isoniazid-resistant organisms
on admission to treatment, who discharged them-
selves prematurely from treatment or who had
bacteriologically active disease at one year.
The results in the present series of patients do not
compare unfavourably with other follow-up series
reported from technically advanced countries (and
covering approximately the same period of time,
namely, 1956-62), especially in view of the very
severe disease under treatment in the Madras series.
Thomas (1965) reported a failure rate of 4.8 %
among 679 sputum-positive patients notified in
Birmingham during the years 1957-58 and followed
up for five years (77 more were untraceable and
their failure rate is not known). Home (1964;
personal communication, 1965) had a failure rate of
1.8 % in a hospital series of 771 sputum-positive
patients followed up during 1955-60 in Edinburgh.
CONCLUSION
The 5-year findings abundantly confirm that the
results of domiciliary chemotherapy, as carried out
in this study, are sufficiently close to the results of
sanatorium treatment to suggest that it is appro-
priate to treat the majority of patients at home
(Tuberculosis Chemotherapy Centre, Madras, 1959;
Velu et al., 1960a; Devadatta et al., 1961), despite
the adverse environmental factors of poor diet,
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overcrowded living conditions and long hours of 1961a) or over a 5-year period (Kamat et al., 1966 2),
work often involving strenuous physical activity in comparison with those of the patients treated in
(Ramakrishnan et al., 1961b; 1966 1). It has also sanatorium in the first year. Considered together,
been shown that the family contacts of the patients these studies have firmly established the value of
who were treated at home were exposed to no well-organized domiciliary chemotherapy, even in
special risk, either in the first year (Andrews et al., the most adverse environmental, economic and
1960) or over a 2-year period (Ramakrishnan et al., dietary circumstances.
IX. SUMMARY
1. A total of 193 patients was admitted to a
controlled comparison of home and sanatorium
treatment of pulmonary tuberculosis, all patients
receiving a standard regimen of isoniazid plus PAS
for one year. The present report deals with the
progress of all these patients (96 home, 97 sana-
torium) during the second, third, fourth and fifth
years.
2. Of the 193 patients, 163 (82 home, 81 sana-
torium), who had drug-sensitive organisms initially,
were included in the main analysis and 30 were
excluded because they did not conform to this or
other important criteria.
3. Of the 163 patients in the main analysis, 130
had bacteriologically quiescent disease at one year,
10 had disease of bacteriologically doubtful status
and 19 had active disease; four had died, three from
tuberculosis and one from a non-tuberculous cause.
4. Of the 130 patients with bacteriologically
quiescent disease at one year, 126 (57 home, 69
sanatorium) were randomly allocated to treatment
during the second year, either with isoniazid alone
or with a placebo, calcium gluconate; 65 (23 cavi-
tated, 42 non-cavitated) received isoniazid and 61
(19 cavitated, 42 non-cavitated) the placebo.
5. During the 4-year period of follow-up, 11
(8.7%) of these 126 patients had a bacteriological
relapse, eight of them in the first year of follow-up.
 Of the 57 home patients, four (7 %) had a relapse, as
compared with seven (10%) of 69 sanatorium
patients. Of 84 patients with no residual cavitation
at one year, seven (17 %) of 42 who received calcium
gluconate had a relapse, as compared with none of
the 42 who received isoniazid (P<0.02). Of the 42
patients with residual cavitation at one year, one
(5 %) of 19 who received calcium gluconate had a
relapse, as compared with three (13 %) of the 23 who
received isoniazid. Six of eight patients in the
1 See article on page 553 of this issue.
calcium series and one of three in the isoniazid series
had a relapse with isoniazid-sensitive organisms.
6. Sixty patients, who received isoniazid alone in
the second year and had bacteriologically quiescent
disease at two years, were allocated at random
to treatment in the third year, 30 to isoniazid alone
and 30 to the placebo. There were no relapses in
either group during the third, fourth or fifth years.
7. Of 18 (14 %) patients who produced an iso-
lated positive culture, only one had a bacteriological
relapse subsequently.
8. Of the 10 patients with disease of bacterio-
logically doubtful status at one year, three had a
bacteriological relapse; in all three, the positive
culture at 12 months proved to be the commence-
ment of a relapse. All 10 patients had bacterio-
logically quiescent disease at five years.
9. All of the 19 patients in the main analysis who
had bacteriologically active disease at one year
received further chemotherapy. At five years, 13 had
bacteriologically quiescent disease, two had active
disease and four had died, three from tuberculosis
and one from a non-tuberculous cause.
10. Of the 30 patients excluded from the main
analysis, those who had isoniazid-resistant orga-
nisms on admission and those who discharged them-
selves prematurely from treatment had, relatively
frequently, an unfavourable outcome at five years.
11. Of the total of 193 patients admitted to the
study, eight died from non-tuberculous causes
during the 5-year period. Of the remaining 185, 90 %
had bacteriologically quiescent disease at five years,
4 % had active disease and 6 % had died of pulmonary
tuberculosis. The proportion of patients who had
quiescent disease at five years was very similar for
the home and the sanatorium series, being 90%
and 89 %, respectively.
2 See article on page 517 of this issue.
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RÉSUMÉ
Le Centre de Chimiothérapie de la Tuberculose à
Madras, Inde, a suivi durant cinq ans l’évolution de la
tuberculose pulmonaire chez 193 malades récents traités
(97 au sanatorium et 96 à domicile) par l’association iso-
niazide-PAS pendant un an. Pour des raisons diverses,
et notamment l’existence d’une résistance aux médica-
ments, 30 d’entre eux furent exclus de l’enquête princi-
pale, qui ne concerna dés lors que 163 cas pharmaco-
sensibles, dont 82 traités à domicile et 81 au sanatorium.
Aprés cette année de traitement, la guérison bactério-
logique était obtenue chez 130 malades; chez 10 autres,
elle ne pouvait être affirmée avec certitude; dans 19 cas,
l’affection restait bactériologiquement active. Quatre
décès furent observes, dont 3 dus à la tuberculose et 1 à
une autre cause. Parmi les 130 patients ainsi négativés
aprés un an de traitement, 126 (57 à domicile, 69 au
sanatorium) reçurent au cours de la 2e année soit de
l’isoniazide seul (65 sujets, dont 23 atteints de lésions
cavitaires) soit du placebo, sous forme de gluconate de
calcium (61 sujets, dont 19 atteints de lesions cavitaires).
Durant la période d’observation de quatre ans succé-
dant à la 1re année de traitement, 11 rechutes bactério-
logiques, soit 8,7%, furent notées chez ces 126 malades,
dont 8 au cours de la 1re année d’observation. Pour les
57 malades soignés à domicile, le taux des rechutes fut
de 7% (4 cas), pour les hospitalisés, de 10% (7 cas). Sur
les 84 patients sans lésions cavitaires résiduelles à l’issue
de la 1re année de traitement, 7 (17%) des 42 cas traités
par placebo présentèrent une rechute; on n’en observa
aucune chez ceux qui reçurent de l’isoniazide. Sur les
42 malades présentant des cavités résiduelles après la
1re année de traitement, 5 % (1 cas) des 19 sujets qui
reçurent du placebo et 13% (3 cas) des 23 sujets qui
reçurent de l’isoniazide furent victimes de rechutes.
Dans 6 cas sur 8 après administration de placebo, et dans
1 cas sur 3 après traitement par l’isoniazide, les bacilles
isolés lors des rechutes étaient sensibles à l’isoniazide.
Soixante malades traités par l’isoniazide seul durant
la 2e année et négativés après cette période reçurent au
cours de la 3e année soit de l’isoniazide (30 cas), soit
du placebo (30 cas). On ne nota aucune rechute dans
ces deux groupes pendant les 3e, 4e et 5e années de sur-
veillance. Sur 18 malades (14%) ayant présenté une
culture positive à une seule occasion, 1 seul eut une
rechute par la suite.
Trois rechutes survinrent chez 10 malades bactériolo-
giquement « douteux » à l’issue de la 1re année de traite-
ment, la positivité de la culture, dans ces 3 cas, ayant
signé le début de la rechute. Ces 10 malades, après les
cinq années d’observation, donnaient des cultures néga-
tives.
Le traitement chimiothérapique fut poursuivi chez les
19 patients présentant une affection bactériologiquement
active après la 1re année de traitement. A l’expiration
des cinq années de surveillance, 13 étaient négativés,
2 donnaient encore des cultures positives et 4 étaient
décédés, dont 3 de tuberculose et 1 d’affection non
tuberculeuse.
Ceux des 30 malades exclus de l’enquête qui étaient
porteurs de bacilles pharmaco-résistants ou qui aban-
donnèrent le traitement prématurément présentèrent de
manière relativement fréquente un tableau clinique
défavorable à la fin de la période d’observation de
cinq ans.
Il y eut, parmi les 193 malades soumis à l’enquête,
8 décès dus à une cause non tuberculeuse. Sur les 185
sujets restants, on notait, après cinq ans, 90% de guéri-
sons bactériologiques et 4 % de tuberculoses pulmonaires
évolutives, cependant que 6 décès par tuberculose pulmo-
naire avaient été enregistrés.
La proportion des guérisons bactériologiques à l’issue
de la période d’observation était très voisine chez les
personnes traitées à domicile ou au sanatorium (90% et
89 % respectivement).
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